News and Trends 7 Oct 2016 Will SynBio replace the French Wine Industry? Ava Winery is creating cheap, sustainable and customizable wine without grapes, yeast or fermentation. The company plans to commercialize its first product in the coming months, will they be able to steal customers from the most famous French wine companies? Ava Winery claims that 90% of tasters cannot tell its prototype apart from traditional wine. The […] October 7, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2016 NASH Maverick continues Rampage with €34M Cash Injection Genfit just added €34M to its cash pile through private placement to bankroll the development of its succeeding lead candidate, Elafibranor. Genfit has had a good year. Earlier this year, the company enrolled its first patient in Phase III clinical trails for Non-Alcoholic Stato-Hepatitis (NASH), and last month, it launched a new non-invasive diagnostic program. It’s […] October 6, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2016 New UK Hero Will Fight Against Non-Small Cell Lung Cancer Achilles Therapeutics was born yesterday in the UK with a €15M funding round. The company will focus on the development of personalized neo-antigentherapies for non-small lung cancer. The newborn Achilles Therapeutics made its debut yesterday with a splashy fundraising round and a licensing agreement. The startup has exclusive rights to develop and commercialize any neo-antigen technology that […] October 6, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Oct 2016 A new Immuno-Oncology biotech’s Small Molecule hits the Clinic Since we interviewed Karus Therapeutics last year, the company has come quite a way! The Oxford-based biotech has just sent its first drug to the clinic. We first met Karus Therapeutics a year ago to talk about their small molecule therapies for cancer and inflammatory disease. The company has entered the immuno-oncology fray and is developing a […] October 6, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2016 €365M deal for a Danish ‘DNA barcode’ Drug Screening Platform The giant Amgen has offered Nuevolution €365M to develop oncology and neuroscience drugs. The small Danish Biotech claims to count with an unprecedented drug discovery platform that can screen billions of compounds way faster and at a lower cost than the big players. Despite its small size, Nuevolution is experienced in collaborating with big Pharma like Merck, Novartis, […] October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2016 New Link found between the Microbiome and “Genetic Obesity” Researchers at King’s College London have found a new link between gut microbiome diversity (or, more specifically, the lack of it) and a particularly troubling kind of obesity. This finding could also help explain the inheritability of this disease. The explosive growth of the Microbiome field promises a whole new type of therapies, but this […] October 5, 2016 - 3 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2016 New Psoriasis Antibody Therapy puts pressure on Best-Seller drug Humira New results from a Phase III trial show that guselkumab, an antibody therapy for the autoimmune disease plaque psoriasis, is performing better than the number one best-seller drug Humira (adalimumab) from AbbVie. The new drug is expected to be commercially available as early as 2018. Since MorphoSys licensed guselkumab to Janssen Biotech, in 2007, the drug has been performing […] October 5, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2016 CRISPR will Win the Nobel Prize, but When? Not this year… Nobel Prize week has kicked off with the announcement of Physiology and Medicine recipient: it wasn’t the CRISPR crowd, but Yoshinori Ohsumi for his work on autophagy. As Derek Lowe puts it, CRISPR “is absolutely, positively going to win a Nobel; the only question is when.” Well, it didn’t manage last year, nor this year. […] October 4, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2016 A Secretive new Oncology Biotech has made a Dramatic Debut Carrick Therapeutics has burst onto the oncology scene with a massive round of fundraising, reeling in almost €100M to become Europe’s cancer leader. Since its foundation last year, oncology upstart Carrick Therapeutics has mostly stayed off the radar. That changed yesterday, when it announced a splashy fundraising round of €85M ($95M) to propel it to the top of […] October 4, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2016 One Step Closer to an HIV Cure That Can Eliminate the Latent Virus HIV has completely disappeared from the blood of a patient in clinical trials. The new HIV treatment that can target the virus even in its dormant state by activating latent infected cells and could possibly become the first HIV cure available. These initial results show that the new therapy, developed in the UK, may be effective in curing HIV. One of 50 […] October 4, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2016 Top 10 European Biotech Entrepreneurs Under 30 in 2016 As a young entrepreneur myself, I’m always impressed by other young entrepreneurs with crazy and ambitious ideas. Here are the most inspiring innovators under 30 years in European Biotech this year! Disclaimers first! Yes, this ranking is obviously very subjective. Yes, I did look for women, but as a reflection of the gender imbalance in biotech […] October 4, 2016 - 6 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2016 Researchers Find New Weak Spots to Develop an HIV Cure Last week we published a thorough review on current approaches for an HIV cure, which may be available as soon as 2020. Academia has come up with two additional strategies that could make a huge difference in the study of HIV. HIV affects 36.7 million people in the world and caused 1.1 million deaths last year. Plenty of resources […] October 3, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email